BE(2)-C Xenograft Model Overview

The BE(2)-C xenograft model is derived from a human neuroblastoma cell line, established from a patient with metastatic neuroblastoma. Neuroblastoma is a pediatric cancer that arises from neural crest cells and is often associated with poor prognosis due to its aggressive nature, rapid growth, and tendency to metastasize to distant organs such as bone marrow, liver, and lymph nodes. The BE(2)-C xenograft model is a valuable tool for studying the biology of neuroblastoma, its metastatic mechanisms, and for evaluating novel therapeutic strategies. Given the model’s metastatic potential and the high levels of resistance to chemotherapy, BE(2)-C is widely used to investigate new drug candidates, including those targeting neural differentiation pathways and tumor microenvironment interactions.

Request a Custom Quote for BE(2)-C Xenograft Model

Biological and Molecular Characteristics

BE(2)-C cells express various markers indicative of neuroblastoma, including neurotrophin receptors (TrkA and TrkB) and the neuroblastoma-specific surface antigen GD2. The cells also express high levels of MYCN, a proto-oncogene that is frequently amplified in high-risk neuroblastoma and contributes to tumorigenesis, poor prognosis, and resistance to therapy. BE(2)-C cells exhibit a high degree of genetic instability and have a complex chromosomal profile, often showing MYCN amplification and alterations in tumor suppressor genes like p53. The model is particularly valuable for testing therapies that target MYCN or pathways involved in neuroblastoma differentiation and growth. BE(2)-C xenografts also present a robust immune-suppressive tumor microenvironment, making them relevant for immunotherapy studies.

Marker	Expression Level	Function
MYCN	High	Oncogene amplification contributing to tumor progression and therapy resistance
TrkA	Moderate	Neurotrophin receptor involved in differentiation and survival of neuroblastoma cells
TrkB	Moderate	Neurotrophin receptor promoting neuroblastoma cell survival
GD2	High	Tumor-specific antigen expressed on neuroblastoma cells

In Vivo Model Development and Tumorigenicity

The BE(2)-C xenograft model is typically established by subcutaneously implanting BE(2)-C cells into immunocompromised mice, such as NOD/SCID or NSG mice. Upon implantation, the cells form rapidly growing tumors that resemble human neuroblastoma in terms of histology and metastatic behavior. The tumors exhibit the classic features of neuroblastoma, including high cellularity, frequent necrosis, and the presence of neural differentiation markers. BE(2)-C xenografts are highly vascularized, facilitating studies on angiogenesis and tumor growth. The model is also used to study metastasis, as BE(2)-C cells have a high tendency to spread to the liver, bone marrow, and lymph nodes, closely mimicking the clinical metastatic patterns observed in human neuroblastoma.

In addition to subcutaneous implantation, BE(2)-C cells can also be implanted orthotopically into the adrenal glands or retroperitoneal space, which more closely replicates the natural site of origin for neuroblastoma tumors. This orthotopic model allows for the study of tumor growth and metastasis in a more clinically relevant setting, enhancing the model’s utility in preclinical research for drug testing and cancer biology studies.

Request a Custom Quote for BE(2)-C Xenograft Model

Histopathology and Immunohistochemical Profile

Histopathological analysis of BE(2)-C xenografts shows tumor cells that are highly cellular with a prominent presence of neuroblasts and some areas exhibiting neural differentiation. The tumors often contain dense areas of necrosis, which are common in rapidly growing neuroblastomas. Immunohistochemical staining reveals strong expression of MYCN and the neurotrophin receptors TrkA and TrkB, confirming the neuroblastoma origin of the tumors. Additionally, the tumor cells show high expression of GD2, a tumor-specific antigen that is being explored as a therapeutic target for neuroblastoma. BE(2)-C xenografts also exhibit markers of angiogenesis, including CD31 staining, which identifies new blood vessels within the tumor, highlighting the tumor’s need for a robust blood supply to support its rapid growth. Furthermore, the tumors show elevated levels of immune cell infiltration, which can be assessed for studies on immune checkpoint inhibition and other immunotherapy approaches.

Preclinical Applications and Drug Response

The BE(2)-C xenograft model is widely used to evaluate new therapeutic agents for neuroblastoma, particularly those targeting MYCN, a key driver of tumorigenesis and resistance in neuroblastoma. The model is highly relevant for testing therapies that target neurotrophin receptors (TrkA and TrkB), which play crucial roles in tumor survival and differentiation. Additionally, BE(2)-C xenografts are employed to assess the efficacy of anti-cancer agents such as small molecule inhibitors, chemotherapies, and novel agents targeting the tumor microenvironment.

Given the model’s aggressive nature and resistance to conventional therapies, BE(2)-C is frequently used to investigate combination therapies, including those that combine chemotherapy with immunotherapies or targeted inhibitors. Monoclonal antibodies targeting GD2, such as dinutuximab, are of particular interest in the treatment of neuroblastoma, and BE(2)-C xenografts are commonly used for evaluating their effectiveness in preclinical models. Furthermore, BE(2)-C is increasingly being utilized to evaluate novel immunotherapy approaches, including immune checkpoint inhibitors and CAR-T cell therapies, which are gaining traction in the treatment of neuroblastoma.

Request This Model

To request the BE(2)-C xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for BE(2)-C Xenograft Model